Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: GI Permeability Change in Response to Aquamin® [Phase 2]
Phase 2 trial assessing GI permeability changes in response to Aquamin® in Ulcerative Colitis; results completed and posted.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Long-term Extension Study of Ustekinumab in Pediatric Participants [Phase 3]
Long-term extension study of ustekinumab in pediatric participants (Phase 3) for Crohn disease, ulcerative colitis, and related psoriatic ar…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]
Phase 3 pediatric study evaluating guselkumab in moderately to severely active ulcerative colitis is active not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis [Phase 3]
Phase 3 pediatric trial update for mirikizumab in moderately to severely active ulcerative colitis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab [Phase 3]
Phase 3 trial assessing change in disease activity in adults with moderate-to-severe Ulcerative Colitis treated with risankizumab versus ved…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis [Phase 3]
Phase 3 trial evaluating oral tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis [Phase 2]
Phase 2 clinical trial update on ABX464 assessing long-term safety and efficacy in moderate to severe active ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis [Phase 3]
An extension study for treatment of moderately to severely active ulcerative colitis in Phase 3 is ongoing (ACTIVE_NOT_RECRUITING).
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis [Phase 2]
Phase 2 dose-finding trial update for SAR443122 in adults with ulcerative colitis (inactive/not recruiting).
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis [Phase 3]
An extension Phase 3 clinical trial for treatment of moderately to severely active ulcerative colitis is ongoing (Extension Study).
-
EMA approval · 2026-04-24EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
The EMA has authorised Stelara (ustekinumab) in the EU for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]
A Phase 3 induction trial is evaluating the efficacy and safety of Duvakitug in participants with moderately to severely active ulcerative c…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE） [Phase 4]
Phase 4 trial comparing upadacitinib to infliximab as second-line therapy for acute severe ulcerative colitis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety [Phase 4]
Phase 4 trial evaluating efficacy and safety of an interleukin-23 monoclonal antibody for inflammatory bowel disease is currently recruiting…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
This clinical trial update notes ongoing Seattle Children's Hospital research evaluating spatial transcriptomics in inflammatory bowel disea…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 clinical trial update describing a study of long-acting antibodies, alone and in combinations, for moderate to severe ulcerative col…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care [NA]
This clinical trial update describes a multimodal randomized controlled trial to improve the transition of patients with Crohn's disease fro…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Association Between LRG and Histologic Remission in Ulcerative Colitis
This clinical trial investigates the association between LRG levels and histologic remission in ulcerative colitis and is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Predictors of Prognosis in IBD Patients
A clinical trial is investigating predictors of prognosis in patients with inflammatory bowel diseases, including ulcerative colitis and Cro…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis [Phase 3]
A Phase 3 clinical trial is evaluating Afimkibart (RO7790121) in children with moderately to severely active ulcerative colitis, with recrui…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Treatment of UC [NA]
A completed trial update evaluating the efficacy and mechanism of fecal microbiota transplantation for ulcerative colitis in Bai ethnicity p…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of SAR442970 in adult participants with ulcerative colitis; recruiting.